On April 3rd, Ispire announced that it had priced its initial public offering of 2.7 million common shares at $7.00 per share. Additionally, the company granted the underwriters a 45-day option to purchase up to an additional 405,000 common shares to cover any over-allotments.
These stocks are expected to begin trading on the Nasdaq Capital Market on April 4, 2023, with the stock code "ISPR". The initial public offering is expected to be completed on April 6, 2023, subject to customary closing conditions.
The funds raised from this issue will be used for:
Approximately 35% of funds will be used to develop manufacturing businesses in Vietnam and the United States. Around 25% will be allocated for research and development activities, including the development of new products and electronic cigarette technologies. Roughly 20% will be directed towards marketing and promoting the company's branded products, with the remaining 20% being allocated for general administrative and operational expenses. Additionally, two selling shareholders are offering a total of 1.75 million common shares in accordance with the prospectus.
Reference:
Ispire Technology Inc. has announced the pricing of its initial public offering.
Related reading:
Inspire will reduce the planned size of its IPO by half, but maintain its price at $6 to $8 per share.
Ispire has submitted an IPO application to be listed on the NASDAQ stock exchange.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
